ISPAD Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
E. Cengiz is a scientific advisor for Eli Lilly, Novo Nordisk, Adocia and Arecor. TD has received speaker's honoraria and research support from or has consulted for Astra Zeneca, Bayer, Boehringer, Dexcom, Eli Lilly, Lifescan, Medtronic, Novo Nordisk, Provention Bio, Roche, Sanofi, Ypsomed and is a shareholder of Drea Med Ltd. TA, JF, DB, SH, MP, E. Codner have no disclosures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“has been postulated, but in 2013 EMA concluded that insulin glargine–containing medicines (Lantus, Optisulin, Sanofi) for diabetes do not show an increased risk of cancer.(64)”
Management of diabetes and hyperglycemia in hospitals.
Clement, S., Braithwaite, S. S., Magee, M. F., Ahmann, A., Smith, E. P., Schafer, R. G., Hirsch, I. B., & on behalf of the Diabetes in Hospitals Writing Committee (2004) · Diabetes Care · doi:10.2337/diacare.27.2.553 · Cited by 1,266 · cited 1×
“In addition, it can be used as a bridge to the longer-acting basal insulins given in the evening when transitioning from IV insulin in the morning or during the honeymoon period.(27,30)”
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407
Mudaliar, S. R., Lindberg, F. A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., & Henry, R. R. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1501 · Cited by 276
Cengiz, E., Xing, D., Wong, J. C., Wolfsdorf, J. I., Haymond, M. W., Rewers, A., Shanmugham, S., Tamborlane, W. V., Willi, S. M., Seiple, D. L., et al. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12030 · Cited by 243 · cited 8×
“There is rarely a predictable treatment regimen that always applies to all persons, particularly for children and adolescents with T1D.”
ResultInfluentialSelf-citationTreatment of diabetic ketoacidosis with subcutaneous insulin aspart
Umpierrez, G. E., Cuervo, R., Karabell, A., Latif, K., Freire, A. X., & Kitabchi, A. E. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1873 · Cited by 227
Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3249 · Cited by 219 · cited 1×
“can be given once a day at any time of the day as long as 8 h has elapsed since the previous injection.(54)”
BackgroundHome, P. D. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01580.x · Cited by 212
Female reproduction and type 1 diabetes: From mechanisms to clinical findings
Codner, E., Merino, P. M., & Tena-Sempere, M. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms024 · Cited by 182 · cited 1×
“Higher BGL may be observed during the luteal phase of the menstrual cycle mediated by progesterone.(87,88) Distribution of Daily Insulin Dose: In children and young people”
BackgroundHeise, T., Pieber, T. R., Danne, T., Erichsen, L., & Haahr, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0514-8 · Cited by 182
Self-citationDanne, T., Lüpke, K., Walte, K., von Schuetz, W., & Gall, M.-A. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3087 · Cited by 153 · cited 1×
“• Detemir is most commonly given twice daily in children.(37,90) When transitioning to detemir from NPH, the same doses can be used to start with, but may require an increase in detemir dose according to SMBG results.”
BackgroundSelf-citationKorytkowski, M. T., Salata, R. J., Koerbel, G. L., Selzer, F., Karslioglu, E., Idriss, A. M., Lee, K. K. W., Moser, A. J., & Toledo, F. G. S. (2009) · Diabetes Care · doi:10.2337/dc08-1436 · Cited by 149
Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis
Umpierrez, G. E., Jones, S., Smiley, D., Mulligan, P., Keyler, T., Temponi, A., Semakula, C., Umpierrez, D., Peng, L., Cerón, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0169 · Cited by 120 · cited 1×
“Regular and rapid-acting and ultra-rapid insulins are equally suited for IV therapy.(160) Regular insulin has traditionally been used for IV infusion for inpatient management of diabetes.”
BackgroundBolli, G. B., Kerr, D., Thomas, R., Torlone, E., Sola-Gazagnes, A., Vitacolonna, E., Selam, J. L., & Home, P. D. (2009) · Diabetes Care · doi:10.2337/dc08-1874 · Cited by 119
Thalange, N., Deeb, L., Iotova, V., Kawamura, T., Klingensmith, G., Philotheou, A., Silverstein, J., Tumini, S., Ocampo Francisco, A., Kinduryte, O., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12263 · Cited by 91
Self-citationMenstrual Cycle Effects on Insulin Sensitivity in Women with Type 1 Diabetes: A Pilot Study
Trout, K. K., Rickels, M. R., Schutta, M. H., Petrova, M., Freeman, E. W., Tkacs, N. C., & Teff, K. L. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0004 · Cited by 75
Albright, E. S., Desmond, R., & Bell, D. S. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.632 · Cited by 75 · cited 1×
“While the ideal is to minimize injections and keep glargine to a once daily administration, there are situations that may warrant twice a day regimen.(35,36)”
BackgroundEffects of the Anatomical Region Used for Insulin Injections on Glycemia in Type I Diabetes Subjects
Bantle, J. P., Neal, L., & Frankamp, L. M. (1993) · Diabetes Care · doi:10.2337/diacare.16.12.1592 · Cited by 70
Randløv, J., & Poulsen, J. U. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200209 · Cited by 61
Hallschmid, M., Jauch-Chara, K., Korn, O., Mölle, M., Rasch, B., Born, J., Schultes, B., & Kern, W. (2010) · Diabetes · doi:10.2337/db09-1493 · Cited by 61
Berghaeuser, M., Kapellen, T., Heidtmann, B., Haberland, H., Klinkert, C., Holl, R., & for the DPV-Science-Initiative and the German working group for insulin pump treatment in paediatric patients (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00416.x · Cited by 58
Biester, T., Blaesig, S., Remus, K., Aschemeier, B., Kordonouri, O., Granhall, C., Søndergaard, F., Kristensen, N. R., Haahr, H., & Danne, T. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12116 · Cited by 53
Self-citationGlucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0218-x · Cited by 42
Moving toward the ideal insulin for insulin pumps
Cengiz, E., Bode, B., Van Name, M., & Tamborlane, W. V. (2016) · Expert Review of Medical Devices · doi:10.1586/17434440.2016.1109442 · Cited by 38
Self-citation
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Aronson, R., Biester, T., Leohr, J., Pollom, R., Linnebjerg, H., LaBell, E. S., Zhang, Q., Coutant, D. E., & Danne, T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15063 · Cited by 14
“These insulins may be particularly useful for pumps and automated insulin delivery systems.(6) Ultra rapid lispro (URLi; Lyumjev) is an insulin lispro formulation containing two locally acting excipients, treprostinil and citrate.”
BackgroundSelf-citation
Metadata
- Authors
- Cengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Ehtisham, S., Fairchild, J., Jarosz‐Chobot, P., Ng, S. M., Paterson, M., & Codner, E.
- Venue
- Pediatric Diabetes
- Publisher
- Hindawi Limited
- Published
- 2022-12
- Volume
- 23
- Issue
- 8
- Pages
- 1277-1296
- ISSN
- 1399-543X (ISSN-L)
- 1399-5448
- OpenAlex
- W4312179390
- Cited by
- 93
- References
- 29
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.